10.1038bjc.2016.327.ann

T1 Condition 848 852 IL-6
T2 CL 726 741 OSCC cell lines
T3 Protein 478 521 humanised anti-human IL-6 receptor antibody
T4 Condition 897 901 cell
T5 Condition 1028 1032 IL-6
T6 Condition 24 46 tumour malignancy IL-6
T7 Condition 499 503 IL-6
T8 Protein 726 730 OSCC
T9 Intervention 680 708 IL-6-mediated radioresistant
T10 Protein 1414 1418 OSCC
T11 Condition 680 684 IL-6
T12 Condition 1271 1275 IL-6
T13 Gene_or_gene_product 1112 1128 Nrf2-antioxidant
T14 Biomarker 867 878 tocilizumab
T15 Level 395 415 radioresistant cells
T16 Protein 332 336 OSCC
T17 Organism 1385 1393 patients
T19 Protein 349 353 OSCC
T20 Intervention 746 753 tissues
T21 Condition 946 950 IL-6
T22 Condition 174 178 cell
T23 Gene 1028 1098 IL-6 promotes the activation of not only the downstream molecule STAT3
T24 Condition 304 308 IL-6
T25 Protein 280 289 molecular
T26 CL 349 364 OSCC cell lines
T27 Condition 410 414 cell
T28 Condition 132 136 IL-6
T29 Protein 190 194 OSCC
T30 Condition 454 458 IL-6
T31 Condition 782 786 IL-6
T32 Level 867 902 tocilizumab sensitised tumour cells
T33 Protein 555 558 DNA
T34 Condition 731 735 cell
T35 Condition 816 820 cell
T36 Biomarker 463 474 tocilizumab
T37 Gene_or_gene_product 652 668 Nrf2-antioxidant
T38 Protein 981 984 DNA
T39 Condition 160 188 oral squamous cell carcinoma
T40 Condition 354 358 cell
T41 Protein 370 374 OSCC
R1 Relation Arg1:T22 Arg2:T29